CD38 as a therapeutic target

Molecular Medicine

Volumn 12, Issue 11-12, 2006, Pages 345-346

  Stevenson, George T ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD38 ANTIGEN; FC RECEPTOR; HUMAX CD38; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD38; RETINOID; SYNDECAN 1; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; CANCER CELL CULTURE; CONFERENCE PAPER; CYTOLYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MULTIPLE MYELOMA; PHAGE DISPLAY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD38; CELL LINE, TUMOR; HUMANS; LEUKEMIA; LYMPHOMA, B-CELL; MICE; MICE, SCID; MULTIPLE MYELOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 33947633987     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-00082.Stevenson     Document Type: Conference Paper

References (10)

1. Deaglio S, Mehta K, Malavasi F. (2001) Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 25:1-12.
2. Chan CS, Wormsley SB, Pierce LE, Peter JB, Schechter GP. (1990) B-cell surface phenotypes of proliferating myeloma cells: target antigens for immunotherapy. Am. J. Hemntol. 33:101-9.
3. Hoffmann C et al. (2005) AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood. 106:1762-9.
4. Rochford R, Hobbs MV, Garnier JL, Cooper NR, Cannon MJ. (1993) Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc. Natl. Acad. Sci. U. S. A. 90:352-6.
5. Stevenson FK et al. (1991) Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 77:1071-9.
6. Ojo E, Wigzell H. (1978) Natural killer cells may be the only cells in normal mouse lymphoid cell populations endowed with cytolytic ability for antibody-coated tumor target cells. Scand. J. Immunol. 7:297-306.
7. Verfaillie CM, Miller JS. (1994) CD34+/CD33-cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3-supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells. Blood. 84:1442-9.
8. Goldmacher VS et al. (1994) Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood. 84:3017-25.
9. Mehta K, Ocanas L, Malavasi F, Marks JW, Rosenblum MG. (2004) Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells. Mol. Cancer Ther. 3:345-52.
10. Gao Y, Camacho LH, Mehta K. (2006) Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon-γ/interleukin-1β- dependent apoptosis of endothelial cells: Implications in the etiology of retinoic acid syndrome. Leuk. Res. in press.